

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-22 (canceled)

23. (currently amended) A fusion protein characterized in that it comprises ~~the amino acid sequences of different allergens belonging to the non-specific Lipid Transfer Protein (ns-LTPs) family~~ Parj1 and Parj2 of the *Parietaria judaica* species, in that said allergens sequences lack one or more of the four disulphide bridges present in ~~the sequences of the~~ wild type allergens, at least one in the amino terminal region comprised between amino acid residues 1 and 30₁ and in that said allergens sequences maintain essentially the same length as ~~the sequences of~~ wild type allergens; wherein said protein comprises the amino acid sequence SEQ ID NO: 4.

Claims 24-32 (canceled)

33. (currently amended-withdrawn) A method for ~~diagnostic or therapeutic treatment in vivo and/or in vitro~~ using the fusion protein according to claim ~~[[25]]~~ 23, the method comprising administration of said protein to a patient ~~or cell~~.

34. (withdrawn) A method according to claim 33 for specific immunotherapy (SIT) treatment of allergies, the method comprising administration to a patient of said protein as a hypoallergenic immunologic agent in the specific immunotherapy (SIT) treatment of allergies.

35. (withdrawn) A method according to claim 33 for treatment of rhinitis, conjunctivitis, urticaria, angioedema, eczema, dermatitides, asthma, or anaphylactic shock, the method comprising administration to a patient of said protein in treatment of rhinitis, conjunctivitis, urticaria, angioedema, eczema, dermatitides, asthma, or anaphylactic shock.

36. (currently amended-withdrawn) A method ~~according to claim 33~~ for preparation of a DNA vaccine, the method comprising mixing DNA coding for the fusion ~~[[said]]~~ protein according to claim 23 in a DNA vaccine.

37. (currently amended) A pharmaceutical composition comprising the fusion protein according to claim 23 ~~[[25]]~~ and a pharmaceutically acceptable excipient.

38. (previously presented) The pharmaceutical composition according to claim 37 in the form of a solution, suspension, emulsion, cream, ointment or implant.

39. (previously presented) The pharmaceutical composition according to claim 37, for parenteral, subcutaneous, intramuscular, intravenous, topical, or oral administration or for subcutaneous implantation.

40. (currently amended-withdrawn) A method for preparation of the fusion protein according to claim ~~[[25]]~~ 23, the method comprising mutating ~~producing suitably mutated~~ amino acid sequences of allergens Parj1 and Parj2 of the *Parietaria judaica* species ~~different allergens~~ and linking them directly or via a spacer for chemical synthesis or by expression, in the form of fusion protein comprising the amino acid sequence SEQ ID NO: 4, in a genetically modified host cell.

41. (withdrawn) The method for preparation according to claim 40, further comprising transforming a host cell with an expression vector comprising DNA coding for the amino acid sequence SEQ ID NO: 4 ~~sequences in fused form, which is mutated via site-specific mutagenesis in one or more codons coding for one or more cysteine residues.~~

Claims 42-43 (canceled)

44. (previously presented) A method for preparation of the pharmaceutical composition

according to claim 37, the method comprising mixing said protein in an immunologically active amount with a pharmaceutically acceptable excipient.

Claims 45-48 (canceled)

49. (new-withdrawn) A method according to claim 33, wherein said protein is prepared in the form of a solution, suspension, emulsion, cream, ointment or implant.

50. (new-withdrawn) A method according to claim 33, wherein said protein is parenterally, subcutaneously, intramuscularly or intravenously administered.

51. (new-withdrawn) A method according to claim 33, wherein said protein is topically administered.

52. (new-withdrawn) A method according to claim 33, wherein said protein is orally administered.

53. (new-withdrawn) A method according to claim 33, wherein said protein is administered by subcutaneous implantation.

54. (new-withdrawn) A method for using the fusion protein according to claim 23, the method comprising administration of said protein to a cell.